COMMUNIQUÉS West-GlobeNewswire

Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
22/11/2024
Indivior selected GABA B PAM drug candidate for development in substance use disorders (SUD) and starts IND enabling studies Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 22, 2024 - Addex [...]
HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan
22/11/2024
— Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024 — — Milestone payment to be made to HUTCHMED from Takeda — — Fruquintinib already launched in several regions including the [...]
BioAdaptives, Inc. Announces 5 Unique Products Ready for Phased Entry Into the Nutritional Marketplace
22/11/2024
LAS VEGAS, Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioAdaptives Inc. (OTC: BDPT) ushered in a new direction by appointing James Keener as CEO on May 21, 2024. Previous management retired, and Keener began focusing on products [...]
Notice of AGM
22/11/2024
DXS INTERNATIONAL PLC (AQSE: DXSP) Notice of 2024 Annual General Meeting The Board of DXS International plc (“the Company” or “DXSP”), the AQSE Growth Market quoted healthcare information and digital clinical decision [...]
Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event
22/11/2024
MELBOURNE, Australia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore presented early this morning at the 21 st Virtual [...]
Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C
21/11/2024
MIPLYFFA, the first FDA-approved treatment for Niemann-Pick disease type C, is available at Zevra’s specialty pharmacy for dispense AmplifyAssist™ , Zevra’s comprehensive patient support program, in place to address [...]
BioXcel Therapeutics Announces Proposed Public Offering
21/11/2024
NEW HAVEN, Conn., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines [...]
High Haven Celebrates "Danksgiving" Cannabis Event with Green Wednesday and Holiday Deals Across Illinois Locations
21/11/2024
WOODRIDGE, Ill., Nov. 21, 2024 (GLOBE NEWSWIRE) -- High Haven Dispensary , recognized as Illinois' top-rated cannabis retailer, invites cannabis enthusiasts to its 2nd Annual "Danksgiving" event on Wednesday, November [...]
Teladoc Health to Participate in Upcoming Investor Conference
21/11/2024
PURCHASE, NY, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, announced today that Chuck Divita, chief executive officer, and Mala Murthy, chief [...]
BioAge Labs to Present at Upcoming Investor Conferences
21/11/2024
RICHMOND, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by [...]
Kane Biotech to Release Third Quarter 2024 Financial Results on November 28, 2024
21/11/2024
Conference Call to be held on December 3, 2024 WINNIPEG, Manitoba, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”) will release its third quarter 2024 financial results [...]
Lifecore Biomedical Hosts Virtual Investor Day
21/11/2024
CHASKA, Minn., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it hosted a [...]
BrightSpring Health Services, Inc. to Participate in Two Upcoming Investor Conferences
21/11/2024
LOUISVILLE, Ky., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) announced today that Company management will participate at two upcoming virtual [...]
Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway
21/11/2024
WOBURN, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it has [...]
Seer Ranked Number 57 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
21/11/2024
Attributes 2,440% revenue growth to increased adoption of its Proteograph™ Product Suite and exciting discoveries made by Seer customers across multiple areas of biology and disease REDWOOD CITY, Calif., Nov. 21, 2024 ( [...]
CAMP4 Reports Third Quarter 2024 Financial Results
21/11/2024
- Completed Initial Public Offering (IPO) of common stock, raising gross proceeds of $82.1M - Single Ascending Dose (SAD) portion of Phase 1 study of CMP-CPS-001 completed; safety data anticipated in Q1 2025 - Entered [...]
Korro to Participate in Upcoming Investor Conferences
21/11/2024
CAMBRIDGE, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both [...]
Inventiva reports 2024 Third Quarter Financial Information¹
21/11/2024
Cash and cash equivalents at €13.9 million, as of September 30, 2024. Revenues of €1.3 million for the first nine months of 2024. On July 18, 2024, Inventiva issued royalty certificates for an amount of €20.1 million. [...]
Inventiva publie ses informations financières du 3ème trimestre 2024¹
21/11/2024
Trésorerie et équivalents de trésorerie à 13,9 millions d’euros au 30 septembre 2023. Chiffre d’affaires de 1,3 millions d’euros sur les neuf premiers mois de 2024. Emission de certificats de redevance le 18 juillet [...]

Pages